{"gao_id": "GAO-20-118", "published": "2020-01-29T12:00:00Z", "released": "2020-01-29T07:00:00Z", "summary": "The Drug Enforcement Administration collects industry-reported data on the sale and purchase of controlled substances and prescription drugs, including opioids. The data supports DEA\u2019s investigations into whether drugs have been diverted to the illegal marketplace. DEA\u2019s systems don\u2019t provide real-time analysis, but more robust analysis is possible. For example, DEA could use computer algorithms to proactively identify patterns and trends in drug distribution\u2014e.g., to see...", "title": "Drug Control: Actions Needed to Ensure Usefulness of Data on Suspicious Opioid Orders", "topics": ["Data management", "Pharmacy", "Information systems", "Health care standards", "Pharmaceutical industry", "Deaths", "Substance abuse", "Reporting requirements", "Database management systems", "Law enforcement", "Drug control", "Policies and procedures", "Health care providers", "Point of sale systems", "Legal counsel", "Criminal investigations", "Performance measurement", "Pharmacist", "Drug enforcement", "Suspicious activities", "Prescription drugs", "Controlled substances", "Patient care", "Compliance oversight", "Federal law enforcement", "Justice and Law Enforcement", "Supply chain management", "Drug overdose", "Best practices", "Drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-118", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-118-highlights.pdf"}, {"title": "Full Report (53 pages)", "url": "https://www.gao.gov/assets/gao-20-118.pdf"}, {"title": "Accessible PDF (59 pages)", "url": "https://www.gao.gov/assets/710/706896.pdf"}]}